Skip to main content
SpringerLink
Log in

CDX2 testing + FOLFOX for CDX2-negative colon cancer patients cost-effective strategy

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Alarid-Escudero F, et al. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis. Value in Health : 2 Nov 2021. Available from: URL: https://doi.org/10.1016/j.jval.2021.07.019

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

CDX2 testing + FOLFOX for CDX2-negative colon cancer patients cost-effective strategy. PharmacoEcon Outcomes News 892, 9 (2021). https://doi.org/10.1007/s40274-021-08204-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08204-0

Search

Navigation